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RVs induce inflammation and remodeling
Leukotriene pathway and inflammation
Hypothesis
Anti-leukotriene treatment of epithelial cells with or 
without exposure to supernatants of RV-infected 
PBMCs may inhibit RV-induced up-regulation of 
inflammatory cytokines.
Methods
• PBMCs isolation: healthy donor – non atopic-non astmatic
• BEAS-2B cell culture
• In-vitro infection of BEAS-2B cells and/or PBMCs with A1B
• In-vitro treatment of BEAS-2B cells and/or PBMCs  with 
Montelukast (cysLT receptor antagonist)or MK-886 (FLAP 
inhibitor)
• Incubation at 33°C, 5% CO2 for 48 hours
• Evaluation of the concentration of inflammatory 
cytokines: IL-8, RANTES, IL-11, IL-6, IP-10
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Results(II) RANTES
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Results(III) IL-6
0
1000
2000
3000
4000
5000
6000
7000
8000
I
L
-
6
 
(
p
g
/
m
l
)
BEAS-2B, IL-6 release (drug treated PBMCs)
*** *** *** ***
**
**
*** ***
0
2000
4000
6000
8000
10000
12000
I
L
-
6
 
(
p
g
/
m
l
)
BEAS-2B, IL-6 release (PBMC, drug treated)
*** ** **
Results(V) IP-10
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Results(IV) IL-11
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Conclusion
Anti-leukotriene treatment of RV-infected bronchial
epithelial cells suppresses epithelial RV-mediated
pro-inflammatory (IL-6, IL-8, RANTES, IP-10) and
anti-inflammatory (IL-11) cytokine response.
These observations may represent an indirect
mode of action of anti-leukotriene medication in
virus-induced asthma.
